30 Jul 2013, BioSpectrum Bureau , BioSpectrum
Singapore: San Francisco-based Ascendancy Healthcare has tied up with Quintiles to get help from the contract research giant in order to leverage on China's growing pharma market.
Quintiles will be advising Ascendancy on which compounds to license in a deal that will last 2.5 years. Quintiles will will lend clinical research services and market access assistance in China and other Asian markets.
"Ascendancy intends to buy the China rights to late-stage therapies worldwide, and Quintiles' expertise will help it execute the plan. We are in active discussions with innovative pharma and life sciences firms and expect to announce our first product licensing deal in the second half of this year," said that Ms Sandy Zweifach, CEO, Ascendancy.